StockData
BioAge Labs, Inc. logo

BioAge Labs, Inc. (BIOA) stock

BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$5.10−0.12 (-2.30%)

Close on Nov 17, 2026Market cap $234.07MP/E –Yield –

BioAge Labs operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

BioAge Labs's operating cash flow for the twelve months ending Jun 30, 2026 was -$87.60M. For fiscal 2025 it was -$81.63M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$81.63M–
FY2024Dec 31, 2024-$51.52M–
FY2023Dec 31, 2023-$37.36M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.26M–
Q1 FY2026Mar 31, 2026-$24.05M–
Q4 FY2025Dec 31, 2025-$28.25M–
Q3 FY2025Sep 30, 2025-$16.04M–
Q2 FY2025Jun 30, 2025-$19.97M–
Q1 FY2025Mar 31, 2025-$17.36M–
Q4 FY2024Dec 31, 2024-$5.14M–
Q3 FY2024Sep 30, 2024-$14.93M–
Q2 FY2024Jun 30, 2024-$15.78M–
Q1 FY2024Mar 31, 2024-$15.67M–
Q4 FY2023Dec 31, 2023-$8.50M–

More BioAge Labs figures

See a number that looks wrong?